FDA PCAC Recommends Peptides for the 503A Bulks List

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that reviews bulk drug substances nominated for inclusion on the Section 503A Bulks List — the list of ingredients that state-licensed traditional compounding pharmacies are permitted to use when preparing customized medications pursuant to a valid prescription. Over two days in July 2026, the committee reviewed seven peptides that have become widely used in the wellness and research markets despite lacking FDA-approved drug products.

Day 1: BPC-157, KPV, TB-500, MOTS-c — All Recommended

On July 23, 2026, PCAC reviewed four peptides nominated for indications spanning wound healing, inflammatory disorders, metabolic conditions, and osteoporosis. FDA reviewers themselves recommended against adding these substances to the list, citing limited clinical and nonclinical safety and effectiveness data. The committee nonetheless voted in favor of all four.

• BPC-157 — recommended for inclusion. A pentadecapeptide fragment studied for gastrointestinal and musculoskeletal healing.
• KPV — recommended for inclusion. A tripeptide fragment of α-MSH with anti-inflammatory activity in preclinical models of IBD and dermatologic disease.
• TB-500 (Thymosin β4 fragment) — recommended for inclusion by the closest margin: 8 in favor, 6 opposed, 1 abstained. Studied in tissue repair and angiogenesis research.
• MOTS-c — recommended for inclusion. A mitochondrial-derived peptide studied for insulin sensitivity, metabolic homeostasis, and osteoporosis.

Several committee members explicitly argued that patients are already obtaining these peptides from unregulated online vendors and that allowing licensed compounding pharmacies to prepare them under oversight would improve quality control and reduce risk relative to the current gray-market supply.

Day 2: Emideltide (DSIP), Semax, Epitalon

On July 24, 2026, the committee reviewed three additional peptides nominated for proposed uses including opioid withdrawal, chronic insomnia, narcolepsy, cerebral ischemia, migraine, and trigeminal neuralgia. FDA reviewers again concluded that the available evidence did not sufficiently demonstrate safety and effectiveness.

• Emideltide (DSIP) — not recommended. The vote was 7 against, 6 in favor, 1 abstained.
• Semax — reviewed with extended debate over limited clinical evidence balanced against patient demand.
• Epitalon — reviewed with the same tension between preclinical longevity literature and the absence of large controlled human trials.

What "Recommended for the 503A List" Actually Means

Inclusion on the 503A Bulks List is not the same as FDA approval of a drug product, and it does not establish that a substance is safe or effective. It permits state-licensed 503A compounding pharmacies to use the substance when preparing patient-specific prescriptions, subject to all other statutory requirements of Section 503A of the Federal Food, Drug, and Cosmetic Act.

PCAC's recommendations are advisory and non-binding. FDA independently evaluates the committee's vote alongside the underlying scientific record, public comments submitted to the docket, historical compounding practices, and broader public health considerations before issuing any final regulatory action through notice-and- comment rulemaking. Timelines for finalization vary considerably.

Statutory Criteria FDA Applies

Under Section 503A, FDA weighs several factors when evaluating a bulk substance nomination:

• The physical and chemical characterization of the substance.
• Safety information, including nonclinical toxicology and any clinical data.
• Evidence of effectiveness for the proposed compounded use.
• Historical use of the substance in compounded medications.
• Whether a clinical need exists to compound the substance, particularly where no FDA-approved alternative is available.

Why This Vote Matters for the Peptide Market

If FDA ultimately adopts PCAC's Day-1 recommendations, BPC-157, KPV, TB-500, and MOTS-c would become available through regulated 503A compounding channels for patient-specific prescriptions. That would represent the first formal regulatory pathway for these peptides in the United States and would materially change the landscape currently dominated by unregulated online vendors. It would not make these peptides available over the counter, and it would not authorize manufactured drug products or mass distribution.

The Day-2 outcomes — particularly the narrow vote against DSIP — indicate that the committee is drawing a real line at the strength of available human data. Peptides with primarily preclinical or small-cohort European literature face a materially harder path than those with a broader base of published research.

Research-Use Status Is Unchanged

None of the peptides discussed at the July 2026 PCAC meeting are currently FDA-approved drug products. Whether or not FDA finalizes their inclusion on the 503A Bulks List, they remain — as of this writing — reference compounds supplied strictly for in-vitro and preclinical laboratory research outside of a regulated compounding pharmacy setting. BioPrime products are sold on that basis only.

References

• U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026. Available at fda.gov/advisory-committees.
• Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. April 16, 2026.
• Bharti AK. FDA Advisory Committee Recommends Four Peptides for 503A Compounding List Despite Limited Evidence. Pharmacally. July 2026.
• Regulatory Affairs Professionals Society (RAPS). FDA advisory committee backs controversial peptides. July 23, 2026.
• American Journal of Managed Care. FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week. July 23, 2026.
• Orrick, Herrington & Sutcliffe LLP. FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting. July 21, 2026.
• 503Pharma. PCAC Day 1: Yes on All Four Peptides. July 24, 2026.
• Section 503A, Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a).